Hefei Lifeon Pharmaceutical Co., Ltd.

SZSE:003020 Stock Report

Market Cap: CN¥3.8b

Hefei Lifeon Pharmaceutical Past Earnings Performance

Past criteria checks 3/6

Hefei Lifeon Pharmaceutical has been growing earnings at an average annual rate of 17.5%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 2.1% per year. Hefei Lifeon Pharmaceutical's return on equity is 10.2%, and it has net margins of 13.4%.

Key information

17.5%

Earnings growth rate

9.4%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-2.1%
Return on equity10.2%
Net Margin13.4%
Last Earnings Update31 Mar 2024

Recent past performance updates

Hefei Lifeon Pharmaceutical's (SZSE:003020) Profits May Not Reveal Underlying Issues

Apr 29
Hefei Lifeon Pharmaceutical's (SZSE:003020) Profits May Not Reveal Underlying Issues

Recent updates

Hefei Lifeon Pharmaceutical (SZSE:003020) Has Announced A Dividend Of CN¥0.50

May 23
Hefei Lifeon Pharmaceutical (SZSE:003020) Has Announced A Dividend Of CN¥0.50

Investors Still Aren't Entirely Convinced By Hefei Lifeon Pharmaceutical Co., Ltd.'s (SZSE:003020) Earnings Despite 25% Price Jump

May 22
Investors Still Aren't Entirely Convinced By Hefei Lifeon Pharmaceutical Co., Ltd.'s (SZSE:003020) Earnings Despite 25% Price Jump

Hefei Lifeon Pharmaceutical's (SZSE:003020) Profits May Not Reveal Underlying Issues

Apr 29
Hefei Lifeon Pharmaceutical's (SZSE:003020) Profits May Not Reveal Underlying Issues

Revenue & Expenses Breakdown

How Hefei Lifeon Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:003020 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 241,42319164096
31 Dec 231,90122766385
30 Sep 232,21021064481
30 Jun 232,61824270585
31 Mar 232,76322870073
01 Jan 232,57920967674
30 Sep 222,50321767475
30 Jun 222,42918767568
31 Mar 222,35317867167
31 Dec 212,27317265066
30 Sep 212,18316160952
30 Jun 212,07615355654
31 Mar 211,99114849451
31 Dec 201,89413543343
30 Sep 201,80912740847
30 Jun 201,75812038445
31 Mar 201,71110937336
31 Dec 191,65010536337
31 Dec 181,4259229524
31 Dec 171,1677714418
31 Dec 161,028679312
31 Dec 14962541070
31 Dec 13878471080

Quality Earnings: 003020 has high quality earnings.

Growing Profit Margin: 003020's current net profit margins (13.4%) are higher than last year (8.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 003020's earnings have grown by 17.5% per year over the past 5 years.

Accelerating Growth: 003020's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 003020 had negative earnings growth (-16.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).


Return on Equity

High ROE: 003020's Return on Equity (10.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.